Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

• Main Authors: Jing-Xin Li, PhD (Author), Li-Hua Hou, PhD (Author), Fan-Yue Meng, MSc (Author), Shi-Po Wu, PhD (Author), Yue-Mei Hu, BS (Author), Qi Liang, BS (Author), Kai Chu, MSc (Author), Zhe Zhang, BS (Author), Jun-Jie Xu, PhD (Author), Rong Tang, MSc (Author), Wen-Juan Wang, MSc (Author), Pei Liu, ProfPhD (Author), Jia-Lei Hu, MSc (Author), Li Luo, MSc (Author), Rong Jiang, MSc (Author), Feng-Cai Zhu, MSc (Author), Wei Chen, PhD (Author)
• Format: Book
• Published: Elsevier, 2017-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: The 2013-15 Ebola virus disease epidemic in west Africa greatly accelerated the development of Ebola vaccine. We aimed to analyse the immune persistence induced by one shot of an adenovirus type-5 vector-based Ebola virus vaccine up to 6 months and the effect of boosting with a...